Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.

Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device

SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025.

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025.

Merit Medical Announces Resignation of President, Joseph Wright

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term

Becton, Dickinson and Co.

Cardinal Health

McKesson

Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI.

4 Stocks to Watch Amid Dental Supplies Industry Challenges

West Pharmaceutical Services

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?

MMSI or WST: Which Is the Better Value Stock Right Now?

The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival.

MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial

Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Fundus Camera market was valued at US$459.40 million in 2024 and is anticipated to hit US$665.85 million by 2033 from 2025 to 2033 with a compound annual growth rate of 4.21%. The primary reason for this growth stems from the demand for more developed diagnostics within the eyes, mainly because of retinal disorders that have been on the rise across the globe. A fundus camera is a medical imaging device specific in the application of ophthalmology to capture high resolution images of the internal eye, with emphasis on the retina, optic disc, and macula. It illuminates and photographs the retina through the pupil to provide critical details necessary for diagnostics and management procedures in various eye conditions. Fundus cameras thus play an instrumental role in detecting retinal disorders including diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal detachment. These conditions often progress in a gradual manner but may go unnoticed until they start impairing vision seriously. In that case, early detection via the use of fundus photography will give time to intervene before more serious vision loss takes place. There are mydriatic, non-mydratic, and hybrid types available, and there are also handheld or portable types for easier access. Apart from diagnosis, follow up of disease progression and effectiveness of the treatment being provided makes fundus imaging a tool more essential in eye care. Growth Drivers for the Fundus Camera Market

Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

Merit Medical's WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI)

MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.

Merit Medical Stock Gains 37.9% Year to Date: What's Behind the Rally?

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?

BDX or MMSI: Which Is the Better Value Stock Right Now?

Merit Medical (MMSI) possesses solid growth attributes, which could help it handily outperform the market.

Is Merit Medical (MMSI) a Solid Growth Stock? 3 Reasons to Think "Yes"

Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term

SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility.

Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical

Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.

MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Brian Lloyd - Chief Legal Officer & Corporate Secretary Joe Wright - President Raul Parra - Chief Financial Officer Conference Call Participants John Young - Canaccord Jayson Bedford - Raymond James Jason Bednar - Piper Sandler David Rescott - R.W. Baird Mike Matson - Needham Craig Bijou - Bank of America Securities Jim Sidoti - Sidoti & Company Michael Petusky - Barrington Research Steve Lichtman - Oppenheimer Operator Good day, and thank you for standing by.

Merit Medical Systems, Inc. (MMSI) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Merit Medical (MMSI) Q3 Earnings: A Look at Key Metrics

Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.75 per share a year ago.

Merit Medical (MMSI) Q3 Earnings and Revenues Surpass Estimates

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?

BDX vs. MMSI: Which Stock Is the Better Value Option?

Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Merit Medical (MMSI) is Poised to Beat Earnings Estimates Again

SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024.

News for Merit Medical Systems Stock (MMSI)